Thermo Fisher Scientific invests in its Pharma Services business

Thermo Fisher Scientific is investing $150 million in its Pharma Services business to provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing, to meet growing customer demand for biologics. The Monza and Ferentino, Italy, and Greenville, North Carolina sites will be expanded over the next two years, and as requested by customers, the sites will be equipped with aseptic filling lines and isolator technology.
Michel Lagarde, president of pharma services for Thermo Fisher Scientific, said: “These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise. We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them.”